# The Ave-CRT Study for Newly Diagnosed Metastatic Esophageal Squamous Cell Carcinoma

> **NCT03800953** · PHASE2 · UNKNOWN · sponsor: **National Taiwan University Hospital** · enrollment: 26 (estimated)

## Conditions studied

- Esophageal Tumor
- Metastatic Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT03800953
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-20
- **Primary completion:** 2021-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2021-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03800953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03800953, "The Ave-CRT Study for Newly Diagnosed Metastatic Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT03800953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*